| Record Information |
| Version |
3.5 |
| Creation Date |
2006-02-16 02:05:30 -0700 |
| Update Date |
2013-02-08 17:10:51 -0700 |
| HMDB ID |
HMDB01849 |
| Secondary Accession Numbers |
None |
| Metabolite Identification |
| Common Name |
Propranolol |
| Description |
Propranolol is a widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety. --PubChem; Propranolol is a highly lipophilic drug achieving high concentrations in the brain. The duration of action of a single oral dose is longer than the half-life indicates and may be up to 12 hours, if the single dose is high enough (e.g. 80 mg). Effective plasma concentrations are between 10-100 ng/mL. -- Wikipedia; It was the first successful beta blocker developed. Propranolol is commonly marketed by Wyeth under the trade name Inderal. |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- b-Propranolol
- beta-Propranolol
- Dociton
- Euprovasin
- Propanalol
- Propanix
- Propanolol
- Propranololo
|
| Chemical Formula |
C16H21NO2 |
| Average Molecular Weight |
259.3434 |
| Monoisotopic Molecular Weight |
259.157228921 |
| IUPAC Name |
[2-hydroxy-3-(naphthalen-1-yloxy)propyl](propan-2-yl)amine |
| Traditional IUPAC Name |
propranolol |
| CAS Registry Number |
525-66-6 |
| SMILES |
CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12 |
| InChI Identifier |
InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3 |
| InChI Key |
AQHHHDLHHXJYJD-UHFFFAOYSA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Aromatic Homomonocyclic Compounds |
| Class |
Acenes |
| Sub Class |
Naphthalenes |
| Other Descriptors |
- Aromatic Homomonocyclic Compounds
- Aromatic Homopolycyclic Compounds
- propanolamine(ChEBI)
- secondary amine(ChEBI)
|
| Substituents |
- 1,2 Aminoalcohol
- Alkyl Aryl Ether
- Secondary Alcohol
- Secondary Aliphatic Amine (Dialkylamine)
|
| Direct Parent |
Naphthalenes |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
Not Available |
| Application |
Not Available |
| Cellular locations |
- Membrane (predicted from logP)
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
96 °C |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
0.0617 mg/L at 25 °C |
Not Available |
| LogP |
3.48 |
AVDEEF,A (1997) |
|
| Predicted Properties |
|
| Spectra |
|
| 1H NMR Spectrum |
| MS/MS Spectrum Quattro_QQQ 10 |
| MS/MS Spectrum Quattro_QQQ 25 |
| MS/MS Spectrum Quattro_QQQ 40 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 10 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 20 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 30 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 40 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 50 |
| MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) |
| MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) |
| MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) |
| MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) |
| MS/MS Spectrum LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) |
| [1H,13C] 2D NMR Spectrum |
|
| Biological Properties |
| Cellular Locations |
- Membrane (predicted from logP)
|
| Biofluid Locations |
|
| Tissue Location |
|
| Pathways |
Not Available
|
| Normal Concentrations |
|
| Urine |
Detected and Quantified |
|
0.0026 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
|
| Abnormal Concentrations |
|
Not Available |
| Associated Disorders and Diseases |
| Disease References |
None |
| Associated OMIM IDs |
None |
| External Links |
| DrugBank ID |
Not Available |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB022707 |
| KNApSAcK ID |
Not Available |
| Chemspider ID |
4777  |
| KEGG Compound ID |
C07407  |
| BioCyc ID |
Not Available |
| BiGG ID |
Not Available |
| Wikipedia Link |
Propranolol  |
| NuGOwiki Link |
HMDB01849  |
| Metagene Link |
HMDB01849  |
| METLIN ID |
2170  |
| PubChem Compound |
4946  |
| PDB ID |
Not Available |
| ChEBI ID |
8499  |
| References |
| Synthesis Reference |
Not Available |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Obach RS: Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos. 1997 Dec;25(12):1359-69.
Pubmed: 9394025
- Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS: Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos. 2006 Sep;34(9):1600-5. Epub 2006 Jun 21.
Pubmed: 16790553
|
| Enzymes |
|
|
|
|
|
|
|
|
|
|
| Name: |
Cytochrome P450 2D6
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP2D6 |
| Uniprot ID: |
P10635  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
| Name: |
Cytochrome P450 1A2
|
| Reactions: |
- RH + reduced flavoprotein + O2 = ROH + oxidized flavoprotein + H2O [RN:R04122]
|
| Gene Name: |
CYP1A2 |
| Uniprot ID: |
P05177  |
| Protein Sequence: |
FASTA |
| Gene Sequence: |
FASTA |
|
|
|
|
|
|
|
|
|
|
|